20 Healthcare Stocks Moving In Thursday's Pre-Market Session

Gainers

Seneca Biopharma, Inc. SNCA shares moved upwards by 27.78% to $1.05 during Thursday's pre-market session.

Aurora Cannabis, Inc. ACB shares increased by 25.80% to $16.04. The most recent rating by Piper Sandler, on May 15, is at Neutral, with a price target of $10.

IMV, Inc. IMV shares increased by 20.48% to $4. The most recent rating by Wells Fargo, on May 18, is at Overweight, with a price target of $8.

Alterity Therapeutics, Inc. ATHE shares rose 10.75% to $0.72.

Aquestive Therapeutics, Inc. AQST stock moved upwards by 5.99% to $6.55.

Guardion Health Sciences, Inc. GHSI stock moved upwards by 5.75% to $0.52.

Aldeyra Therapeutics, Inc. ALDX stock moved upwards by 5.26% to $4.60. The most recent rating by Oppenheimer, on May 12, is at Outperform, with a price target of $12.

Altimmune, Inc. ALT stock rose 4.95% to $6.36.

HEXO, Inc. HEXO stock moved upwards by 4.66% to $0.51. The most recent rating by Roth Capital, on Mar 31, is at Neutral, with a price target of $1.

Midatech Pharma, Inc. MTP shares moved upwards by 4.61% to $1.59.

 

Losers

Akorn, Inc. AKRX stock declined 24.97% to $0.21 during Thursday's pre-market session.

scPharmaceuticals, Inc. SCPH shares fell 17.82% to $8.90. The most recent rating by HC Wainwright & Co., on May 13, is at Buy, with a price target of $15.

Synlogic, Inc. SYBX stock decreased by 10.29% to $2.18.

Flexion Therapeutics, Inc. FLXN shares decreased by 9.80% to $9.85. The most recent rating by Needham, on May 8, is at Buy, with a price target of $20.

Entera Bio, Inc. ENTX shares fell 8.77% to $2.60.

Surface Oncology, Inc. SURF shares fell 8.51% to $3.55.

Miragen Therapeutics, Inc. MGEN shares fell 8.30% to $0.58.

Ekso Bionics Holdings, Inc. EKSO shares decreased by 7.41% to $3. The most recent rating by Aegis Capital, on Apr 13, is at Buy, with a price target of $15.

DBV Technologies, Inc. DBVT shares fell 6.53% to $4.58. The most recent rating by Citigroup, on Apr 6, is at Buy, with a price target of $10.

Galapagos, Inc. GLPG stock fell 6.01% to $207.98. The most recent rating by Morgan Stanley, on Apr 15, is at Equal-Weight, with a price target of $226.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Pre-Market OutlookMarketsMoversTrading IdeasHealthcare Stocks Pre-Market MoversTop Gainers
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!